Open-label Study of Surufatinib in Japanese Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- William Schelman, MD
Hutchmed
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fukuoka Sanno Hospital
Fukuoka, Japan
- Kyushu University Hospital
Fukuoka, Japan
- Kagawa University Hospital
Kagawa, Japan
- National Cancer Centre Hospital East
Kashiwa-shi, Japan
- Kyoto University Hospital
Kyoto, Japan
- Kyorin University Hospital
Mitaka, Japan
- Aichi Cancer Centre
Nagoya, Japan
- Kansia Electric Power Hospital
Osaka, Japan
- Hokkaido University Hospital
Sapporo, Japan
- Tohoku University Hospital
Sendai, Japan
- National Cancer Centre Hospital
Tokyo, Japan
- Yokohama City University Hospital
Yokohama, Japan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Sept 2021
- Primary completion
- 6 Sept 2024
- Completion
- 17 Jan 2025
- Last update posted
- 16 Sept 2025
- Registered enrollment
- 36
- Registry id
- NCT05077384
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.